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Cell cycle: On target with Myc
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Recent evidence indicates that the c-Myc proto-oncogene
activates transcription of cdc25A. The Cdc25A protein
phosphatase is required both for progression through
mitosis and for Myc-induced apoptosis, making cdc25A
the most attractive Myc target gene identified so far.
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The c-myc proto-oncogene has been extensively studied
and its product is the best-characterized member of the
Myc family of short-lived nuclear phosphoproteins (c-, N-,
L-, S- and B-Myc; for a review of Myc proteins see [1]).
Expression of one or other myc genes is observed in virtu-
ally every human tumour, indicating that Myc function is
very highly selected during carcinogenesis, and is perhaps
mandatory. In normal cells, c-myc expression is tightly reg-
ulated in response to growth signals. Non-proliferating or
quiescent cells generally express no detectable c-myc but
the gene is rapidly induced following mitogenic stimula-
tion and, thereafter, continues to be expressed (at very low
levels) in proliferating cells. Induction of c-myc expression
is both necessary and, at least in certain cell types, suffi-
cient for progression through the first and subsequent cell
cycles. Upon mitogen withdrawal, c-Myc protein is rapidly
cleared from cells, a phenomenon that is facilitated by the
very short half lives of both its mRNA and protein [2,3].
Fibroblasts in which c-Myc is experimentally deregulated
so that the cells can no longer downregulate c-Myc expres-
sion upon mitogen withdrawal become unable to leave the
cell cycle.
Given the growth-promoting properties of c-myc, it may
seem paradoxical that c-myc is also a potent inducer of apop-
tosis [4,5], a cell suicide programme that is, self-evidently,
opposed to cell proliferation. Induction of apoptosis by
c-Myc is promoted by growth-factor deprivation or by phys-
ical or genotoxic trauma [4] and is suppressed by specific
cytokine survival factors or anti-apoptotic proteins such as
Bcl-2 [6–8]. Two main models have been proposed to
explain induction of apoptosis by c-Myc [9]: one posits that
cell death results from a conflict between growth-promot-
ing (Myc-mediated) and growth-arresting signals; the other
presumes that both induction of mitogenesis and induction
of apoptosis are normal functions of Myc, with other signals
determining which eventually occurs. At present, however,
the molecular basis for how c-Myc induces either apoptosis
or cell proliferation remains unknown.
The c-Myc protein is a transcriptional modulator of the
basic helix-loop-helix–leucine zipper (bHLH Zip) family.
The bHLH Zip domain mediates sequence-specific DNA
binding and dimerization with relevant partner proteins
[10]; it lies at the carboxyl terminus of c-Myc, together
with two nuclear localization signals. The amino-terminal
region of c-Myc contains a transcriptional activation
domain. All of these structural features are required for all
known functions of c-Myc — cell transformation, induc-
tion of cell proliferation, c-Myc autoregulation and induc-
tion of apoptosis. This strongly implies that c-Myc exerts
its biological effects as a transcription factor, although
other functions cannot be formally excluded.
The partner protein of c-Myc in vivo is another bHLH Zip
protein, Max. Dimerization of Max with c-Myc is a pre-
requisite for all known c-Myc functions and is required for
sequence-specific DNA binding by c-Myc. Max can also
form homodimers and is the obligate dimerization partner
of another family of bHLH Zip polypeptides, the Mad pro-
teins. Indeed, Myc and Mad proteins compete for binding
to Max which thus lies at the hub of a Myc–Max–Mad
network. Max–Mad dimers antagonize the mitogenic
actions of Myc–Max dimers and recruit various proteins that
function as transcriptional co-repressors. Myc–Max het-
erodimers bind to a DNA consensus sequence, CACGTG,
commonly referred to as the ‘E box’. Interactions are also
observed, however, between c-Myc and so-called ‘non-
canonical’ E box-related binding sites, including the hexa-
mers CATGTG, CATGCG, CACGCG, CACGAG, and
one heptamer, CAACGTG [11].
Because all evidence indicates that c-Myc acts as a tran-
scription factor, there has long been great interest in iden-
tifying genes that are transcriptionally regulated by Myc
— ‘target genes’ — but very few have been identified.
Candidates include the gene for a-prothymosin (function
unknown) [12]; ODC, the gene encoding ornithine decar-
boxylase [13], a rate-limiting enzyme for polyamine
biosynthesis that is essential for progression into S phase;
ECA39, a developmentally regulated gene of unknown
function that is overexpressed in some brain tumours [14];
the tumour suppressor gene p53 [15]; cad, which is
required for de novo synthesis of pyrimidines; eIF-2a,
encoding the eukaryotic translational initiation factor 2a
[16]; and MrDb, which encodes an evolutionarily con-
served RNA helicase of the DEAD-box family [11]. Some
of these genes, such as ODC and cad, are clearly required
in proliferating cells. None, however, can provide a satis-
fying mechanistic explanation for how c-Myc initiates and
maintains cell proliferation or promotes apoptosis.
If c-Myc is such a potent inducer of cell proliferation, it
must presumably interface in some way with the cell-cycle
‘machinery’. Transition through the mammalian cell cycle
is promoted by cyclin-dependent kinases (Cdks) and their
regulatory subunits, the cyclins. During G1 phase of the
cell cycle, cyclin D1–Cdk4 (or cyclin D1–cdk6) and cyclin
E–Cdk2 complexes are active. Both cooperate to phospho-
rylate and inactivate the retinoblastoma protein, pRb,
which, in its hypophosphorylated form, restrains progres-
sion from the G1 phase of the cell cycle into S phase (Fig.
1). Induction of Myc in fibroblasts that have had their cell
cycle arrested by growth to confluence triggers rapid
hyperphosphorylation of pRb and activation of both cyclin
D1- and cyclin E-associated kinase activities in the
absence of significant changes in the absolute amounts of
cyclin–Cdk complexes [17]. Myc-induced activation of the
G1 cyclin complexes leads to up-regulation of cyclin A
mRNA [18], accompanied by transition through the cell
cycle. Thus, the most likely mediators of a role for c-Myc
in cell-cycle entry and progression are the G1 cyclin–Cdks
and their regulators.
A new c-Myc target gene that has been identified in a
recent paper by Galaktionov et al. [19] has many of the
credentials of a mediator between c-Myc and the cell-
cycle regulatory mechanism. This gene, cdc25A, encodes a
crucial G1-specific protein phosphatase that is required for
the initiation of the cell cycle and for its progression
through G1.  Cdks are regulated positively and negatively
by several independent mechanisms. Their activation
requires both association with the appropriate cyclin and
phosphorylation by a Cdk-activating kinase (CAK). Cdk
activity is suppressed by interactions with Cdk-inhibitory
proteins (p16, p21 and p27) and by phosphorylation at
conserved threonine and tyrosine residues, usually at
positions 14 and 15 of the Cdk. Dephosphorylation of
these residues, with concomitant Cdk activation, is medi-
ated by phosphatases of the Cdc25 family. Three human
Cdk-activating phosphatases have been identified:
Cdc25A, which is expressed early in G1 phase; Cdc25B,
expressed during late-G1 phase close to the G1–S-phase
transition; and Cdc25C, which is activated in G2 phase.
Substantial evidence implicates Cdk2, and possibly Cdk4,
as the physiological substrates of Cdc25A whose dephos-
phorylation allows progress through the cell cycle.
Galaktionov et al. [19] showed that cdc25A (and potentially
also cdc25B) mRNA and protein product become abun-
dant following ectopic activation of Myc in mouse and rat
cell lines. This induction of cdc25A mRNA is not affected
by the protein synthesis inhibitor cycloheximide, indicat-
ing that induction of cdc25A mRNA is a direct conse-
quence of c-Myc action on the cdc25A gene and not
dependent on some intermediary gene product induced
by c-Myc. Consistent with this idea, sequence analysis
revealed the presence of three potential Myc–Max
binding sites in the human cdc25A gene. The first two
have the non-canonical nucleotide sequence CATGTG
and lie within the first intron, the third is a canonical
CACGTG E box in the second intron. These three sites
bind c-Myc directly in vitro and are sufficient to confer c-
Myc-dependence on the transcriptional activation of a het-
erologous promoter. Moreover, the locations of the E
boxes in cdc25A resemble those of Myc sites in other Myc
target genes (typically in introns distant from the start of
transcription). By contrast, genes regulated by other
bHLH Zip transcription factors that share specificity for
the Myc E-box motif tend to have E boxes near the start
site for transcription.
The evidence is, thus, very strong that cdc25A is a direct
transcriptional target of c-Myc. Given the ability of
Cdc25A to cause entry of mammalian cells into G1 phase,
it is an excellent candidate for a mitogenic effector of c-
Myc. Indeed, cdc25A and c-myc gene expression patterns
overlap in the mouse. During murine embryogenesis, c-myc
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Model for how c-myc activation leads to progression from G1 phase
through the cell cycle. Myc initiates cdc25A expression. Cdc25A
dephosphorylates Cdk2 (and possibly Cdk4) leading to activation of
these kinases. The active kinase complexes phosphorylate pRb,
resulting in release of free and active E2F protein. Members of the E2F
family of transcription factors are thought to transactivate genes
important for further cell-cycle progression. Active Cdc25A
phosphatase is also necessary for Myc-induced apoptosis [19],
whereas Cdk activity (at least in fibroblasts) seems not to be needed
for induction of cell death [18] (although elevated cyclin D levels may
be important in some forms of neuronal cell death). 
and cdc25A are expressed in most developing embryonic
organs, and in the adult mouse both are expressed in
kidney, liver and heart, albeit at low levels. (As both c-Myc
and cdc25A are essential for cell proliferation, however,
coincident expression in proliferating cells is perhaps not
surprising.)
Because c-Myc induces apoptosis as well as cell prolifera-
tion, might apoptosis also use cdc25A as an effector? Galak-
tionov and colleagues [19] demonstrated that Cdc25A
induces apoptosis in serum-deprived fibroblasts, exactly as
does c-Myc. Moreover, suppression of Cdc25A expression
using antisense RNA substantially diminished the ability
of c-Myc to promote apoptosis. Cdc25A appears, at the
very least, necessary for c-Myc-induced apoptosis; quite
possibly it is also a principal effector of the c-Myc death
pathway. It therefore seems likely that the cell prolifera-
tion and cell death pathways bifurcate downstream of
c-Myc and that both are channelled through Cdc25A.
If cdc25A is the principal effector of c-Myc, is it a proto-
oncogene? Both cdc25A and cdc25B are, like c-myc,
expressed at elevated levels in certain primary breast
tumours. Indeed, this observation first prompted the
investigation of cdc25A regulation by Myc. Many cell-
cycle regulators are expressed at elevated levels in
tumours, however, and this overexpression may often
reflect, rather than cause, the rapid proliferation of tumour
cells. There is little evidence to indicate that deregulated
expression of cdc25A is as ubiquitous as that of c-myc in
tumours, which might imply that the two genes have
subtly different functional attributes. Both cdc25A and
cdc25B share with c-myc the ability to co-operate with Ha-
ras in the oncogenic transformation of cultured primary
rodent fibroblasts [20], however, so they can function as
oncogenes in vitro.
Is cdc25A thus the complete solution to the long-standing
mystery of Myc biology? Almost certainly not. Other Myc
targets are known and there are almost certainly more:
Myc probably serves to coordinate multiple genetic pro-
grammes during cell proliferation. Some of c-Myc’s func-
tions, including induction of apoptosis [21], can occur
throughout the cell cycle but it is unclear whether
Cdc25A has any role later in the cell cycle than G1. There
is also the problem of the kinetics of induction of cdc25A
following c-Myc activation. The induction cdc25A mRNA
was analyzed in mouse cells that express a b-oestradiol-
dependent conditional allele of c-Myc. Although c-myc
activation by steroid was very rapid in this system, the
cdc25A mRNA level peaked only after about eight hours.
It is not immediately obvious why it should take so long
to induce a direct target of c-Myc. A similar time lag was
observed between the appearance of Myc protein and
maximum induction of cdc25A mRNA in quiescent NRK
fibroblasts following mitogenic stimulation: c-Myc protein
was expressed within the first couple of hours after addi-
tion of serum, but cdc25A mRNA expression peaked only
after some 9 hours [22].
Another difficulty that needs to be addressed is the
finding by Steiner et al. [17] that activation of cyclin
E–cdk2 in serum-deprived cells occurs in two steps. The
first is triggered by Myc and involves the release of a
120 kDa cyclin E–cdk2 complex from a 250 kDa inactive
precursor. This dissociation involves, at least in part, loss
of the p27 Cdk inhibitor and is necessary, but not suffi-
cient, to generate full cyclin E–cdk2 kinase activity. In
such mitogen-deprived conditions, Cdc25 phosphatase
activity is limiting and is not induced by Myc activity.
Full activation of Cdc25A, required for cdk2 activation by
dephosphorylation, is only achieved following mitogen
stimulation. Thus, although c-Myc may induce Cdc25A
expression, it is insufficient for full activation of the
phosphatase.
Clearly, these discrepancies need to be explained. One
straightforward approach to testing whether transcrip-
tional up-regulation of cdc25A by Myc is a general mecha-
nism for Myc’s function in mitogenesis (and possibly
apoptosis) is to determine if Myc-dependent regulation
of cdc25A occurs in other cell types and across species —
in particular, whether the Myc/Max binding sites in the
first and second introns of human cdc25A are evolutionar-
ily conserved. Nonetheless, only the most pessimistic
and cautious would argue that cdc25A is anything other
than a terrific c-Myc transcriptional target. It is in the
right place at about the right time, its ‘face’ fits and it is
eminently qualified. Only time will tell whether it is
really up to the job.
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